220 related articles for article (PubMed ID: 23613375)
1. [Early insulin treatment in type 2 diabetes--yes].
Schumm-Draeger PM
Dtsch Med Wochenschr; 2013 May; 138(18):956. PubMed ID: 23613375
[No Abstract] [Full Text] [Related]
2. [Insulin glargine. The most studied basal insulin].
Walter M
MMW Fortschr Med; 2013 Nov; 155(19):70-1. PubMed ID: 24475676
[No Abstract] [Full Text] [Related]
3. ["Very good metabolic control by early insulin administration"].
Schumm-Draeger PM
MMW Fortschr Med; 2012 Jun; 154(12):25. PubMed ID: 22880291
[No Abstract] [Full Text] [Related]
4. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
5. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
6. [Early insulin treatment in type 2 diabetes--no].
Nauck M
Dtsch Med Wochenschr; 2013 May; 138(18):957. PubMed ID: 23613376
[No Abstract] [Full Text] [Related]
7. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
8. Summaries for patients. Comparison of two types of insulin added to diabetes pills in poorly controlled type 2 diabetes.
Ann Intern Med; 2008 Oct; 149(8):I-46. PubMed ID: 18936498
[No Abstract] [Full Text] [Related]
9. [Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
Einecke D
MMW Fortschr Med; 2012 Jun; 154(12):28. PubMed ID: 22880293
[No Abstract] [Full Text] [Related]
10. [Researchers illuminate diabetes therapy].
Pflege Z; 2014 Feb; 67(2):126. PubMed ID: 24730335
[No Abstract] [Full Text] [Related]
11. [Oral treatment of type 2 diabetes mellitus].
Palitzsch KD
Dtsch Med Wochenschr; 2012 Sep; 137(38):1859-68, quiz 1869-72. PubMed ID: 22971973
[No Abstract] [Full Text] [Related]
12. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
Owens DR; Traylor L; Dain MP; Landgraf W
Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
[TBL] [Abstract][Full Text] [Related]
16. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
[TBL] [Abstract][Full Text] [Related]
17. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
Rodbard HW; Cariou B; Zinman B; Handelsman Y; Philis-Tsimikas A; Skjøth TV; Rana A; Mathieu C;
Diabet Med; 2013 Nov; 30(11):1298-304. PubMed ID: 23952326
[TBL] [Abstract][Full Text] [Related]
18. Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.
Joseph JJ; Donner TW
Vasc Health Risk Manag; 2015; 11():107-16. PubMed ID: 25657589
[TBL] [Abstract][Full Text] [Related]
19. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.
Nauck M; Horton E; Andjelkovic M; Ampudia-Blasco FJ; Parusel CT; Boldrin M; Balena R;
Diabet Med; 2013 Jan; 30(1):109-13. PubMed ID: 22937895
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
